Nanoparticulate meloxicam formulations
View Patent ↗The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.
1. An intravenous injection pharmaceutical dosage form comprising:
(a) a liquid dispersion medium selected from the group consisting of water, an aqueous salt solution, safflower oil, ethanol, t-butanol, hexane and glycol;
(b) particles of meloxicam or a salt thereof having an effective average particle size of less than 200 nm; and
(c) polyvinylpyrrolidone and sodium deoxycholate as surface stabilizers adsorbed on the surface of the meloxicam particles,
wherein:
(i) the surface stabilizer are essentially free of intermolecular cross-linkages;
(ii) meloxicam is present in an amount of from about 99.5% to about 0.001%, by weight, based on the total combined weight of the meloxicam and the surface stabilizers; and
(iii) the surface stabilizers are present in an amount of from about 0.01% to about 99.5%, by weight, based on the total combined weight of the meloxicam and the surface stabilizers.
2. The pharmaceutical dosage form of claim 1 , wherein the meloxicam is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.
3. The pharmaceutical dosage form of claim 1 , wherein the effective average particle size of the meloxicam particles is selected from the group consisting of less than 100 nm, less than 75 nm, and less than 50 nm.
4. The pharmaceutical dosage form of claim 1 , wherein the pharmaceutical dosage form further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.
5. A method of making an intravenous injection pharmaceutical dosage form comprising contacting meloxicam particles with polyvinylpyrrolidone and sodium deoxycholate as surface stabilizers in the presence of a liquid dispersion medium selected from the group consisting of water, an aqueous salt solution, safflower oil, ethanol, t-butanol, hexane and glycol for a time and under conditions sufficient to provide the intravenous injection pharmaceutical dosage form comprising meloxicam particles having an effective average particle size of less than 200 nm, wherein:
(i) the surface stabilizers are essentially free of intermolecular cross-linkages;
(ii) meloxicam is present in an amount of from about 99.5% to about 0.001%, by weight, based on the total combined weight of the meloxicam and the surface stabilizers; and
(iii) the surface stabilizers are present in an amount of from about 0.01% to about 99.5%, by weight, based on the total combined weight of the meloxicam and the surface stabilizers.
6. The method of claim 5 , wherein said contacting comprises grinding.
7. The method of claim 6 , wherein said grinding comprises wet grinding.
8. The method of claim 5 , wherein said contacting comprises homogenizing.
9. The method of claim 5 , wherein said contacting comprises:
(a) dissolving the meloxicam particles in a solvent;
(b) adding the resulting meloxicam solution to a solution comprising at least one surface stabilizer; and
(c) precipitating the solubilized meloxicam having at least one surface stabilizer associated with the surface thereof by the addition thereto of a non-solvent.
10. The method of claim 5 , wherein the meloxicam is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.
11. The method of claim 5 , wherein the effective average particle size of the nanoparticulate meloxicam particles is selected from the group consisting of less than 100 nm, less than 75 nm, and less than 50 nm.
12. The method of claim 5 , wherein the pharmaceutical dosage form further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.
13. A method of treating a subject in need thereof comprising intravenously injecting to the subject an effective amount of a pharmaceutical dosage form comprising:
(a) a liquid dispersion medium selected from the group consisting of water, an aqueous salt solution, safflower oil, ethanol, t-butanol, hexane and glycol;
(b) particles of meloxicam or a salt thereof; and
(c) polyvinylpyrrolidone and sodium deoxycholate as surface stabilizers,
wherein:
(i) the surface stabilizers are essentially free of intermolecular cross-linkages;
(ii) the meloxicam particles have an effective average particle size of less than 200 nm;
(iii) meloxicam is present in an amount of from about 99.5% to about 0.001, by weight, based on the total combined weight of the meloxicam and the surface stabilizers; and
(iv) the surface stabilizer is present in an amount of from about 0.01% to about 99.5%, by weight, based on the total combined dry weight of meloxicam and the surface stabilizers.
14. The method of claim 13 , wherein the meloxicam is selected from the group consisting of crystalline phase, an amorphous phase, and a semi-crystalline phase.
15. The method of claim 13 , wherein the effective average particle size of the nanoparticulate meloxicam particles is selected from the group consisting of less than 100 nm, less than 75 nm, and less than 50 nm.
16. The method of claim 13 , wherein the pharmaceutical dosage form further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.
17. The method of claim 13 , wherein the method is used to treat a condition selected from the group consisting of conditions in which NSAIDs are contraindicated, arthritic disorders, gastrointestinal conditions, inflammatory conditions, pulmonary inflammation, opthalmic diseases, central nervous systems disorders, pain, fever, inflammation-related cardiovascular disorders, angiogenesis-related disorders, benign tumors, malignant tumors, adenomatous polyps, endometriosis, osteoporosis, dysmenorrhea, premature labor, asthma, fibrosis which occurs with radiation treatment, eosinophil-related disorders, pyrexia, bone resorption, nephrotoxicity, hypotension, arthrosis, joint stiffness, kidney disease, liver disease, acute mastitis, diarrhea, colonic adenomas, bronchitis, allergic neuritis, cytomegalovirus infectivity, apoptosis, lumbago, psoriasis, eczema, acne, burns, dermatitis, ultraviolet radiation damage, allergic rhinitis, respiratory distress syndrome, and endotoxin shock syndrome.
18. The method of claim 13 , wherein the method is used to treat an indication in which anti-inflammatory agents, anti-angiogenesis agents, antitumorigenic agents, immunosuppressive agents, NSAIDs, COX-2 inhibitors, analgesic agents, anti-thrombotic agents, narcotics, or antifebrile agents are typically used.
19. The method of claim 13 , wherein said subject is a human.